CAP37 derivatives (Biolytx)

N/A

Report date: 2025/01/26 17:41:51

Base Information

Drug NameCAP37 derivatives (Biolytx)
Drug Alias NameCAP37(20-44(C26S)) (Biolytix)CAP37(20-44) (Biolytix)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsSkin Diseases, InfectiousEye InfectionsBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiolytx Pharmaceutical Corp
China Registration ClassN/A

Develop Information

Active CompaniesBiolytx Pharmaceutical Corp
Inactive CompaniesN/A
Active IndicationsSkin Diseases, InfectiousEye InfectionsBacterial Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A